Clinical trials conducted in Brazil found that the effectiveness of coronary vaccine developed by Chinese pharmaceutical companies Sinovac Biotech exceeded 50%, but researchers should postpone more information at the company's request.
According to Bloomberg, officials from the Butantan Institute (Butantan? Institut) and St. Paulo stated that the clinical trials of about 13,000 subjects in Brazil showed that the vaccine was "safe to safeefficient".They said that as part of the content of the contract agreement, they were asked not to release the data for the time being, until the test data was thoroughly judged in China.
Jean Gorinchteynia, the head of the health department of St. Paul, said at a press conference: "Our goal is to be more than 50%of the validity of the vaccine.""
Greencin said that the effective data generated by the Brazilian test is different from the results obtained in other countries, but it is not made in detail.He added that the evaluation of the Kochi biology was expected to take 15 days, but it may be shorter. The plan to start inoculation on January 25 should not be delayed as a result.
50%of the validity is the minimum authorization of crown diseases set by the US regulatory agency.The American Pharmaceutical Company Moderna and Pfizer use the vaccine test results of the messenger RNA technology. In large -scale clinical trials, the number of symptomatic cases will be reduced by more than 90%.
Butantan head Dimas Covas said that the vaccine vaccination team in the Brazilian trial did not have cases of crown disease, and the main adverse reaction of the report was mild pain in the injection site.He said that the effectiveness of the vaccine and exceeding Brazil's health regulatory agency ANVISA's requirements for vaccination were still required to be approved.
Copavas said: "There are many tests in Kochi creatures. The important thing is to ensure data consistency." "The company cannot use different standards to analyze the data of the same vaccine, and there are three different vaccines. There are three different vaccines.Effective data. "
The reason for delaying the results of the announcement is not clear.In vaccine or drug tests, patients with different groups or regions usually have slightly different results, and research institutions usually announce various test results respectively.
The Koxing biological vaccine may be more suitable for developing countries because it can be stored at the temperature of normal refrigerators.In contrast, Pfizer and Moderna's messenger RNA vaccine needs to be stored and transported under deep frozen conditions, increasing the complexity of distribution.
In addition to the Brazilian central government, Butantan is also negotiating with Argentina, Uruguay, Peru, Ecuador, and Honduras to sell the Cocye biological vaccine.Copavas claims that Chile negotiates directly with Koxing Bio.
